Samsung Bioepis reported positive top-line results for SB-27, its proposed biosimilar to Merck’s Keytruda (pembrolizumab), including Phase 1 and Phase 3 endpoints. The company said parallel-run studies demonstrated clinical and pharmacokinetic equivalence to the reference product. The update does not include granular endpoint numbers in the provided report, but the parallel design suggests a data strategy aimed at reducing uncertainty and strengthening similarity arguments for regulatory review. For the biosimilar market, the key impact is continued momentum toward an alternative to a blockbuster checkpoint inhibitor, where timing, interchangeability discussions, and pricing pressure depend heavily on the strength of clinical equivalence packages.